Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
Browsing: Science
The compound, known as DT-109, works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver. According to findings published in The Journal of Clinical Investigation, this approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, offering a promising new strategy for treating a disease that remains difficult to manage.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
The breakthrough, described in a study published in Cell, could help overcome some of the biggest obstacles facing cancer immunotherapy, including the difficulty of manufacturing enough immune cells and keeping them active in the body. In experiments involving mice, the engineered cells established themselves in bone marrow, produced new immune cells, and slowed the progression of both blood cancers and solid tumors.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
The breakthrough, described in a study published in Cell, could help overcome some of the biggest obstacles facing cancer immunotherapy, including the difficulty of manufacturing enough immune cells and keeping them active in the body. In experiments involving mice, the engineered cells established themselves in bone marrow, produced new immune cells, and slowed the progression of both blood cancers and solid tumors.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
The breakthrough, described in a study published in Cell, could help overcome some of the biggest obstacles facing cancer immunotherapy, including the difficulty of manufacturing enough immune cells and keeping them active in the body. In experiments involving mice, the engineered cells established themselves in bone marrow, produced new immune cells, and slowed the progression of both blood cancers and solid tumors.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
The breakthrough, described in a study published in Cell, could help overcome some of the biggest obstacles facing cancer immunotherapy, including the difficulty of manufacturing enough immune cells and keeping them active in the body. In experiments involving mice, the engineered cells established themselves in bone marrow, produced new immune cells, and slowed the progression of both blood cancers and solid tumors.